Abstract
The balance between thromboxane A 2 (a vasoconstrictor) and prostacyclin (a vasodilator) may be important in the pathogenesis of Raynaud's phenomenon, Dazoxiben is a selective inhibitor of thromboxane synthetase, with no effect on prostacyclin synthetase. It has been shown to abolish cold induced forearm vasoconstriction in normal volunteers. We have compared its effect with that of placebo in a double blind crossover study in eight patients with severe Raynaud's phenomenon. No consistently clinically useful benefit was demonstrated from three weeks' treatment with dazoxiben, and there were no significant changes in finger temperature or finger blood flow. We conclude that dazoxiben at this dosage is unlikely to be of practical clinical benefit in Raynaud's phenomenon.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
